On November 23, 2020 Imago BioSciences, Inc. ("Imago") a clinical-stage biopharmaceutical company developing innovative treatments for myeloproliferative neoplasms, reported its participation in the Piper Sandler 32nd Annual Healthcare Conference to be held virtually December 1 – 3, 2020 (Press release, Imago BioSciences, NOV 23, 2020, View Source [SID1234571601]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Hugh Young Rienhoff, Jr. M.D., chief executive officer of Imago BioSciences, will participate in a fireside chat with Christopher Andrews. The fireside chat will be pre-recorded and available on the Piper Sandler website to registered attendees beginning on Monday, November 23, 2020 at 10:00 am ET. The Company will host the one-on-one meetings with investors on Monday, November 30, 2020, meetings can be requested exclusively via Piper Sandler.